Research chemicalResearch chemicalDissociativeArylcyclohexylamine

2-Fluorodeschloroketamine (2-FDCK)

Also known as 2-FDCK · 2-Fl-2'-Oxo-PCM · Fluoroketamine

Written by enwyReviewed 4 Aug 20262 sources0 comments

2-Fluorodeschloroketamine (2-FDCK) is a ketamine analogue in which the chlorine is replaced by fluorine, sold as a research chemical and often used as a near-substitute for ketamine. Its potency and duration are broadly similar to ketamine, but human safety data are minimal.

01 Overview

2-FDCK became one of the more common ketamine substitutes on the research-chemical market as ketamine itself came under tighter control. Its effects are reported as closely resembling ketamine in character, potency and duration, making it popular among those seeking a ketamine-like experience.

There is little formal research; knowledge is drawn from anecdote and analytical identification in seized samples. Ketamine-type risks, including bladder toxicity with heavy chronic use, are presumed but not documented.

02 Mechanism

NMDA-receptor antagonist analogous to ketamine, with the fluorine substitution producing broadly similar pharmacology.

03 Dosing

Tier	Dose	Route
Light	20–40 mg	Insufflated
Common	40–90 mg	Insufflated
Common	60–130 mg	Oral

04 Effects

Effect	Magnitude	Evidence
Ketamine-like dissociationReported as closely resembling ketamine in character and duration.		Anecdotal
Analgesia and sedationTypical dissociative pain relief and sedation.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Presumed bladder toxicityKetamine-type cystitis is plausible with heavy chronic use but not documented for 2-FDCK.	Moderate	Presumed, undocumented	Unconfirmed
Dissociative incapacitationHigh doses cause immobilisation with risk of accidents or aspiration.	Moderate	Dose-dependent	Anecdotal

06 Legal status

United States

Possibly controlled as a ketamine analogue

May fall under the Federal Analogue Act. · as of Jan 2026

United Kingdom

Class B controlled drug

Controlled as an arylcyclohexylamine. · as of Jan 2026

07 References

2-Fluorodeschloroketamine identification and reportsPubMed literature

New psychoactive substances: dissociativesEUDA (European Union Drugs Agency)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.